Repeated inhalation of low doses of cat allergen that do not induce clinical symptoms increases bronchial hyperresponsiveness and eosinophil cationic protein levels.
The aim of this study was to investigate whether repeated exposure to subclinical doses of cat allergens, not inducing asthma symptoms, could affect eosinophil cationic protein (ECP) levels in bronchoalveolar lavage (BAL) or in peripheral blood, without the appearance of clinical symptoms. Twelve patients with mild asthma, all sensitized to cats and not exposed to cat allergen at home, underwent a series of inhalations of cat allergen or placebo for 8 days over 2 weeks. A methacholine challenge was performed before and after the allergen and saline exposures, and BAL and blood were sampled for ECP measurements and eosinophil counts. No patients experienced asthma symptoms. However, PD20 methacholine (geometric mean) decreased significantly from 263 microg before to 126 microg after inhalation of allergen. Inhalation of saline did not induce any significant change in PD20. The change in log PD20 before and after cat allergen exposure was statistically different from the change in log PD20 before and after saline. Median ECP levels in BAL and serum increased significantly after allergen exposure, from 0.8 to 3.1 microg/l (p<0.02) and from 15.9 to 31.4 microg/l (p<0.05), respectively. No change was observed after saline inhalations. The change in BAL and serum ECP levels was statistically significant compared to that in the control group. The number of eosinophils did not change, however, nor did IL-5 and RANTES levels in BAL and serum. In conclusion, our results show that (1) exposure of asthma patients to repeated low doses of allergen, which did not provoke any clinical symptoms, is capable of inducing a local eosinophil activation associated with an increase in nonspecific bronchial hyperresponsiveness and (2) the increase in serum ECP levels due to eosinophil activation precedes the occurrence of asthma symptoms and may thus be a marker of allergen exposure in allergic asthma.
de Blay
F
F
Institut National de la Santé et de la Recherche Médicale Unité 425, Hôpital Lyautey, Strasbourg, France. frederic.deblay@chru-strasbourg.fr
Krieger
P
P
Spirlet
F
F
Moreau
L
L
Duvernelle
C
C
Kassel
O
O
Kopferschmitt
M C
MC
Gasser
B
B
Demangeat
C
C
Pauli
G
G
Frossard
N
N
D000280:Administration, Inhalation; D000485:Allergens / Q000008:administration & dosage; D000818:Animals; D001249:Asthma / Q000097:blood / Q000276:immunology / Q000378:metabolism; D001798:Blood Proteins / Q000378:metabolism; D016535:Bronchial Hyperreactivity; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D002415:Cats / Q000276:immunology*; D018946:Chemokine CCL5 / Q000032:analysis / Q000097:blood; D004306:Dose-Response Relationship, Immunologic; D047091:Eosinophil Granule Proteins; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D015848:Interleukin-5 / Q000032:analysis / Q000097:blood; D012260:Ribonucleases
D000485:Allergens; D001798:Blood Proteins; D018946:Chemokine CCL5; D047091:Eosinophil Granule Proteins; D018836:Inflammation Mediators; D015848:Interleukin-5; D012260:Ribonucleases